Table 3.

Univariable and multivariable competing-risks regression models for urethral cancer patients (Urothelial vs. Adenocarcinoma/Urothelial vs. Other variant histology).

	CSM Urothelial vs. Adenocarcinoma				CSM Urothelial vs. Other variant histology
	Univariable		Multivariable		Univariable		Multivariable
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Histology
Urothelial	1.00 (Ref.)	---	1.00 (Ref.)	---	1.00 (Ref.)	---	1.00 (Ref.)	---
Adenocarcinoma/Other variant histology	1.34 (0.96–1.88)	0.09	1.05 (0.73–1.49)	0.3	1.71 (1.10–2.67)	0.02	1.68 (1.06–2.68)	0.03
Race/ethnicity
Caucasian	1.00 (Ref.)	---	1.00 (Ref.)	---	1.00 (Ref.)	---	1.00 (Ref.)	---
African American	2.11 (1.46–3.04)	<0.001	1.83 (1.26–2.66)	0.045	1.73 (1.06–2.83)	0.03	1.49 (0.91–2.43)	0.11
Hispanic	1.27 (0.62–2.58)	0.5	1.22 (0.58–2.56)	0.2	1.07 (0.45–2.54)	0.9	0.95 (0.38–2.38)	0.9
Other	1.45 (0.72–2.93)	0.3	1.12 (0.51–2.46)	0.4	1.30 (0.57–2.97)	0.5	1.23 (0.57–2.68)	0.6
Treatment
Endoscopic/Surgery	1.00 (Ref.)	---	1.00 (Ref.)	---	1.00 (Ref.)	---	1.00 (Ref.)	---
Bi-/Trimodality	2.06 (1.33–3.18)	<0.01	2.05 (1.33–3.15)	<0.001	1.51 (0.89–2.55)	0.13	1.50 (0.88–2.54)	0.14
Systemic chemotherapy	5.93 (3.69–9.54)	<0.001	5.45 (3.33–8.94)	<0.001	2.57 (1.34–4.91)	<0.01	2.42 (1.29–4.53)	<0.001
Unknown	3.21 (1.90–5.44)	<0.001	3.09 (1.79–5.35)	<0.001	2.94 (1.52–5.66)	<0.01	3.10 (1.63–5.9)	<0.001

Univariable and multivariable competing-risks regression models for urethral cancer patients matched for TNM-stage and age for urothelial vs. adenocarcinoma and subsequently for urothelial vs. other histology. CSM, Cancer specific mortality; HR, Hazard ratio; CI, Confidence interval.